Role of human albumin in the management of liver cirrhosis

Aim. To demonstrate the role of concentrated human albumin in cirrhotic patient management.

The main content. Albumin has a clear place in the clinical practice of cirrhotic patients managing. The structure and functions of albumin can be impaired in patients with acute and chronic liver failure, which correlates with the severity of the disease course and can affect its outcome. Intravenous transfusions of highly concentrated (20%) human albumin are necessary to achieve a response to diuretic therapy. Plasma volume expansion should be performed by albumin transfusing after removal of ascitic fluid during a large volume paracentesis in patients with tense ascites.

The administration of albumin is recommended in patients with spontaneous bacterial peritonitis; the aim: to potentiate the action of antibiotics and prevents the development of other complications, such as encephalopathy, progressive liver failure, impaired renal function. The combination of terlipressin with albumin is a first-line therapy in patients with hepatorenal syndrome-acute kidney injury (hepatorenal syndrome of type I according to the old terminology). The same combination is effective in treating another form of renal dysfunction - type II hepatorenal syndrome according to the old classification, i.e. a patient with hepatorenal syndrome does not meet the criteria for acute kidney injury. Recently, the results of a multicenter randomized parallel-group study, Answer (human Albumin for the treatmeNt of aScites in patients With hEpatic cirrhosis) were published, which showed that prolonged weekly use of human albumin contributes to control of ascites, reduces the incidence of infectious complications, episodes of encephalopathy in patients with decompensated cirrhosis. This leads to a decrease in the frequency of repeated hospitalizations, a decrease in mortality, an improvement in the quality of life, and an increase in the overall survival.

1. OuinLan GJ., Martin G.S., Evans T.W. Albumin: Biochemical Properties and Therapeutic Potential. Hepatology. 2005;41(6):1211-1219. doi: 10.1002/hep.20720.

2. Bernardi M., Moreau R., Angeli P, Schnabl B., Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272-1284. doi: 10.1016/j.jhep.2015.07.004.

3. Fernandez J., Claria J., Amorós A., Aguilar F., Castro M., Casulleras M. et al. Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. Gastroenterology. 2019;157(1):149-162. doi: 10.1053/j.gastro.2019.03.021.

4. Baldassarre M., Naldi M., Bartoletti M. et al. The residual native albumin predict albumin disfunction and outcomes in hospitalized cirrhotic patients with acute decompensation and acute-on-chronic liver failure; Digestive and Liver Disease. 2019;51(1):e41. doi: 10.1016/j.dld.2018.11.114.

5. Ivashkin V.T., Mayevskaya M.V., Pavlov C.S., Fedosyina Y.A., Bessonova Y.N., Pirogova I.Y., Garbuzenko D.V. Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association. Rossiyskiy zhurnal gastroehnterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):71-102. (In Russ.). Available at: https://www.gastro-j.ru/jour/article/view/73.

6. The European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024.

7. Bernardi M., Caraceni P, Navickis RJ., Wilkes M.M. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172-1181. doi: 10.1002/hep.24786.

8. Arroyo V., Gines P, Gerbes A.L., Dudley FJ., Gentilini P, Laffy G., Reynolds T.B., Ring-Larsen H., Sholmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome incirrhosis. Hepatology. 1996;23(1):164-176. doi: 10.1002/hep.510230122.

9. Angeli P, Albino G., Carraro P, Pria M.D., Mercel C., Caregaro L., De Bei E., Bortoluzzi A., Piebani M., Gatta A. Cirrhosis and musle cramps: evidence of a casual relationship. Hepatology. 1966;23(2):264-273. doi: 10.1002/hep.510230211.

10. Vidot H., Carey S., Allman-Farinelli M., Shackel N. Systematic review: the treatment of muscle cramps in patients with cirrhosis. Aliment Pharmacol Ther. 2014;40(3):221-232. doi: 10.1111/apt.12827.

11. Ribeiro T.C., Chebli J.M., Kondo M., Gaburri P.D., Chebli L.A., Feldner A.C. Spontaneous bacterial peritonitis: How to deal with this life-threatening cirrhosis complication? Ther Clin Risk Manag. 2008;4(5):919-925. doi: 10.2147/tcrm.s2688.

12. Caruntu F.A., Benea L. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointestin Liver Dis. 2006;15(1):51-56. Available at: https//www.ncbi.nlm.nih.gov/pubmed/16680233.

13. Fasolato S., Angeli P., Dallagnese L., Maresio G. et al. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology. 2007;45(1):223-229. doi: 10.1002/hep.21443.

14. Fernandez J., Tandon P, Mensa J., Garcia-Tsao G. Antibiotic prophylaxis in cirrhosis: Good and bad. Hepatology. 2016;63(6):2019-2031. doi: 10.1002/hep.28330.

15. Shugalei I.V., Garabadzhiu A.V., Ilyushin M.A., Sudarikov А.М. Some Aspects of Effect of Aluminium and Its Compounds on Living Organisms. Ehkologicheskaya khimiya = Ecological Chemistry. 2012;21(3):172-186. (In Russ.) Available at: https://chemjournals.thesa.ru/eco/a/ecol_172.pdf.

16. Gluud L.L., Christensen K., Christensen E., Krag A. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev. 2012;12(9):CD005162. doi: 10.1002/14651858.CD005162.pub3.

17. Facciorusso A., Chandar A.K., Murad M.H., Prokop LJ., Muscatiello N., Kamath P.S., Singh S. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(2):94-102. doi: 10.1016/S2468-1253(16)30157-1.

18. Restuccia T., Ortega R., Guevara M., Gines P., Alessandria C., Ozdogan O. et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004;40(1):140-146. doi: 10.1016/j.jhep.2003.09.019.

19. Rodriguez E., Henrique Pereira G., Sola E., Elia C., Barreto R., Pose E. et al. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation out- comes. Liver Transpl. 2015;21(11):1347-1354. doi: 10.1002/lt.24210.

20. Caraceni P., Riggio O., Angeli P, Alessandria C., Neri S., Foschi F.G. et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. The Lancet. 2018;391(10138):2417-2429. doi: 10.1016/S0140-6736(18)30840-7.